A notable advancement in diabetes management is emerging with the approval of tirzepatide at a dosage of 45mg. This updated formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 agonist, and https://icelisting.com/story22572702/groundbreaking-development-tirzepatide-45mg-for-diabetes-management